Medifast(US:MED)2025-11-03 21:15Financial Performance - Third quarter 2025 revenue decreased 36.2% to $89.4 million from $140.2 million in the same quarter of 2024, primarily due to a 35.0% decrease in the number of active earning OPTAVIA coaches to 19,500[3] - Gross profit for the third quarter 2025 decreased 41.2% to $62.2 million, with a gross profit margin of 69.5%, down from 75.4% in the prior year[4] - The company reported a net loss of $2.3 million, or $0.21 loss per diluted share, compared to a net income of $1.1 million, or $0.10 per diluted share, in the third quarter of 2024[11] - The company's loss from operations was $4.1 million, representing a loss of 4.6% of revenue, compared to an income from operations of 1.5% in the prior-year period[8] Expenses - Selling, general, and administrative expenses (SG&A) decreased 36.0% to $66.2 million, but as a percentage of revenue, SG&A increased to 74.1% from 73.9% year-over-year[5] Future Projections - The company expects fourth quarter 2025 revenue to be in the range of $65 million to $80 million, with diluted loss per share projected between $0.70 and $1.25[13] Balance Sheet - As of September 30, 2025, the company had a strong balance sheet with $173.5 million in cash and no debt, up from $162.3 million at the end of 2024[12] - The total assets decreased to $268.2 million as of September 30, 2025, from $284.2 million at the end of 2024[21] Other Income - Other income increased approximately $2.0 million to $1.4 million, primarily due to the absence of a loss on the company's investment in LifeMD, Inc. common stock that occurred in the same period in 2024[9] Revenue per Coach - The average revenue per active earning OPTAVIA coach was $4,585, down from $4,672 in the same quarter last year[3]